GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » YS Biopharma Co Ltd (NAS:YS) » Definitions » PS Ratio

YS Biopharma Co (YS Biopharma Co) PS Ratio : 1.21 (As of May. 16, 2024)


View and export this data going back to 2023. Start your Free Trial

What is YS Biopharma Co PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, YS Biopharma Co's share price is $1.03. YS Biopharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.85. Hence, YS Biopharma Co's PS Ratio for today is 1.21.

The historical rank and industry rank for YS Biopharma Co's PS Ratio or its related term are showing as below:

YS' s PS Ratio Range Over the Past 10 Years
Min: 0.35   Med: 0.79   Max: 11.79
Current: 1.16

During the past 3 years, YS Biopharma Co's highest PS Ratio was 11.79. The lowest was 0.35. And the median was 0.79.

YS's PS Ratio is ranked better than
91.99% of 999 companies
in the Biotechnology industry
Industry Median: 9.04 vs YS: 1.16

YS Biopharma Co's Revenue per Sharefor the six months ended in Sep. 2023 was $0.40. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.85.

Warning Sign:

YS Biopharma Co Ltd revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of YS Biopharma Co was -16.20% per year.

Back to Basics: PS Ratio


YS Biopharma Co PS Ratio Historical Data

The historical data trend for YS Biopharma Co's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YS Biopharma Co PS Ratio Chart

YS Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23
PS Ratio
- - 1.49

YS Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
PS Ratio Get a 7-Day Free Trial - - - 1.49 -

Competitive Comparison of YS Biopharma Co's PS Ratio

For the Biotechnology subindustry, YS Biopharma Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


YS Biopharma Co's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, YS Biopharma Co's PS Ratio distribution charts can be found below:

* The bar in red indicates where YS Biopharma Co's PS Ratio falls into.



YS Biopharma Co PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

YS Biopharma Co's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.03/0.851
=1.21

YS Biopharma Co's Share Price of today is $1.03.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. YS Biopharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.85.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


YS Biopharma Co  (NAS:YS) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


YS Biopharma Co PS Ratio Related Terms

Thank you for viewing the detailed overview of YS Biopharma Co's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


YS Biopharma Co (YS Biopharma Co) Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.

YS Biopharma Co (YS Biopharma Co) Headlines

From GuruFocus

/DISREGARD RELEASE: YS Biopharma/

By PRNewswire 12-20-2023